Long-Term Treatment Benefit Seen in Relapse-Onset MS

This article originally appeared here.
Share this content:
Long-Term Treatment Benefit Seen in Relapse-Onset MS
Long-Term Treatment Benefit Seen in Relapse-Onset MS

FRIDAY, May 6, 2016 (HealthDay News) -- For patients with relapse-onset multiple sclerosis (MS), disease-modifying therapy protects against long-term disability accrual, according to a study published online May 4 in the Annals of Neurology.

Vilija G. Jokubaitis, Ph.D., from the University of Melbourne in Australia, and colleagues examined predictors of 10-year expanded disability status scale (EDSS) change after treatment initiation in patients with relapse-onset MS. Patients had remained on injectable therapy for at least one day, and were monitored thereafter on any approved disease-modifying therapy or no therapy. Data were included for 2,466 patients who reported post-baseline disability scores during follow-up of at least 10 years.

The researchers found that patients were treated 83 percent of their follow-up time, on average. At 10 years post-baseline, EDSS scores had increased by a median of 1 point. Over 10 years, the annualized relapse rate was predictive of increases in the median EDSS. Greater burden was seen for on-therapy relapses versus off-therapy relapses. There was an independent correlation for cumulative treatment exposure with lower EDSS at 10 years. Over the 10-year observation period, pregnancies were also independently associated with lower EDSS scores.

"We provide evidence of long-term treatment benefit in a large registry cohort, and provide evidence of long-term protective effects of pregnancy against disability accrual," the authors write. "We demonstrate that high-annualized relapse rate, particularly on-treatment relapse, is an indicator of poor prognosis."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Panel Has Tie Vote on New Type 1 Diabetes Drug

FDA Panel Has Tie Vote on New Type ...

Zynquista is a once-daily pill meant to help type 1 diabetes patients manage their blood glucose levels

FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents

FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents

Investigation triggered by meta-analysis showing possible increased mortality in PAD patients at 2 years

Frailty Could Increase Susceptibility for Dementia

Frailty Could Increase Susceptibility for Dementia

Authors say frailty should be considered in clinical care, management of Alzheimer dementia

is free, fast, and customized just for you!




Already a member?

Sign In Now »